Scarica l'app Stockscreener
3.955
2.60%
-0.105
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABCL Giù?
Forum
Previsione
Abcellera Biologics Inc Borsa (ABCL) Ultime notizie
Leerink Partners Initiates Coverage on AbCellera Biologics with "Outperform" Rating and $5.00 Price Target - AInvest
Abcellera Biologics stock hits 52-week high at 4.09 USD By Investing.com - Investing.com Nigeria
AbCellera's Strategic Pivot to Internal Pipelines Fuels Growth Potential in Antibody Therapies - AInvest
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025 - Business Wire
Leerink Partners Initiates AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $5 - 富途牛牛
Abcellera Biologics stock hits 52-week high at 4.09 USD - Investing.com
AbCellera Biologics' 6% Surge: A Technical & Order-Flow Deep Dive - AInvest
Truist Financial Lowers PT on AbCellera Biologics (ABCL) to $10 From $28, Keeps a Buy Rating - MSN
Leerink Partners assumes coverage on AbCellera stock with Outperform rating - Investing.com
AbCellera Biologics' Mysterious 5.7% Spike: A Technical Deep Dive - AInvest
AbCellera Biologics: Fueling Growth Through Strategic Partnerships and R&D Reinvention - AInvest
AbCellera Biologics Secures Patent Validity Affirmation for Microfluidic Cell Culture Technology - Insider Monkey
AbCellera shareholders approve board election and auditor - Investing.com Australia
AbCellera shareholders approve board election and auditor By Investing.com - Investing.com Nigeria
AbCellera Biologics Holds Annual Shareholder Meeting - TipRanks
AbCellera Biologics: The Dilemma Of A Promising Pipeline Alongside Cash Burn (ABCL) - Seeking Alpha
ABCELLERA BIOLG (ABCL) Upgraded to Buy: Here's Why - MSN
AbCellera Biologics (ABCL) Stands Out in Active Option Classes | - GuruFocus
AbCellera Biologics (ABCL) Stands Out in Active Option Classes | ABCL Stock News - GuruFocus
AbCellera Biologics’ Canadian Clinical Trials Approval Sparks Surge - timothysykes.com
AbCellera Biologics Inc. (ABCL): A Bull Case Theory - MSN
Squarepoint Ops LLC Acquires 44,367 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World
AbCellera Biologics Inc. (ABCL) Approved to Begin ABCL575 Trial for Atopic Dermatitis - MSN
AbCellera Biologics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Why AbCellera Biologics Stock Raced Nearly 6% Higher Today - AOL.com
AbCellera (ABCL) Stock Rises on Health Canada Approval - GuruFocus
AbCellera gains Health Canada nod for AD antibody trial By Investing.com - Investing.com South Africa
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 - BioSpace
AbCellera (ABCL) Gains Health Canada Approval for Clinical Trial - GuruFocus
AbCellera Biologics Receives Health Canada Approval for Trial - TipRanks
AbCellera Biologics Gets Health Canada Authorization for Phase 1 Trial of Dermatitis Treatment - marketscreener.com
AbCellera Receives Authorization from Health Canada to Initiate - GuruFocus
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 | ABCL Stock News - GuruFocus
AbCellera receives Health Canada authorization to initiate ABCL575 Phase 1 trial - TipRanks
AbCellera gains Health Canada nod for AD antibody trial - Investing.com
Health Canada Greenlights AbCellera's Novel Antibody Trial for Chronic Skin Disease Treatment - Stock Titan
AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Holdings Boosted by Millennium Management LLC - Defense World
AbCellera Biologics Inc. (ABCL): Analysts See 474% Upside Potential - MSN
AbCellera Biologics Inc. raises US$100M in series A2 financing - McCarthy Tétrault
13 Best Multibagger Stocks to Invest in Now - Insider Monkey
Truist Financial Has Lowered Expectations for AbCellera Biologics (NASDAQ:ABCL) Stock Price - Defense World
Truist cuts AbCellera stock target to $10, maintains Buy By Investing.com - Investing.com South Africa
Truist Securities Lowers Price Target for AbCellera Biologics (A - GuruFocus
Truist cuts AbCellera stock target to $10, maintains Buy - Investing.com Australia
3.69%
2.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):